AAS
ORKA

Ameritas Advisory Services’s Oruka Therapeutics ORKA Stock Holding History

Ameritas Advisory Services’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11
Closed -$540 – 2147
2026
Q1 		$540 Buy
+11
New +$382 ﹤0.01% 1035

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Ameritas Advisory Services's ORKA Position: Q2 2026 in Review

Ameritas Advisory Services sold out of Oruka Therapeutics (ORKA) in Q2 2026, closing a stake of 11 shares — an estimated $540 sold.

Ameritas Advisory Services first reported a position in ORKA in Q1 2026 and held it in 1 quarter. The position peaked at $540 in Q1 2026. 256 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Ameritas Advisory Services reported no remaining Oruka Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Ameritas Advisory Services sold 11 Oruka Therapeutics shares in Q2 2026, an estimated $540.
  • Ameritas Advisory Services first reported a position in Oruka Therapeutics in Q1 2026 and held it in 1 quarter.
  • Ameritas Advisory Services's Oruka Therapeutics position peaked at $540 in Q1 2026.
  • 256 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Ameritas Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.